Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR

Molecular Cancer

Volumn 3, Issue , 2004, Pages

  Lévy, Pascale ^a   Vidaud, Dominique ^a   Leroy, Karen ^c   Laurendeau, Ingrid ^a   Wechsler, Janine ^c   Bolasco, Giulia ^a   Parfait, Béatrice ^a   Wolkenstein, Pierre ^c   Vidaud, Michel ^a   Bièche, Ivan ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GELATINASE B; GENE PRODUCT; MESSENGER RNA; PROTEIN S100B; RAS PROTEIN; SONIC HEDGEHOG PROTEIN; SURVIVIN; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSCRIPTION FACTOR SOX10; RNA;

ADULT; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; EXTRACELLULAR MATRIX; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; MAST CELL; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVE; REAL TIME POLYMERASE CHAIN REACTION; SCHWANN CELL; SENESCENCE; SIGNAL TRANSDUCTION; UPREGULATION; ADOLESCENT; CHEMISTRY; COMPARATIVE STUDY; COMPUTER SYSTEM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; TUMOR GENE;

ERINACEIDAE;

ADOLESCENT; ADULT; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPUTER SYSTEMS; DOWN-REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; MAST CELLS; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SCHWANN CELLS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; UP-REGULATION;

EID: 13644258035     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-3-20     Document Type: Article

References (59)

1. Friedman JM: Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999, 89:1-6.
2. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O'Connell P, et al.: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990, 62:193-201.
3. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, et al.: Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249: 81-186.
4. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR: Abnormal regulation of mammalian p21 ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992, 69:265-273.
5. Ferner RE, Gutmann DH: International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002, 62:1573-1577.
6. Scheithauer B, Woodruff J, Erlandson R: Tumors of the Peripheral Nervous System. 3rd edition. Washington, DC, Armed Forces Institute of Pathology: Atlas of Tumor Pathology. Third Series, Fascicle 24; 1999.
7. Woodruff JM: Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet 1999, 89: 3-30.
8. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF: Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002, 296:920-922.
9. Cichowski K, Jacks T: NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001, 104:593-604.
10. Dasgupta B, Gutmann DH: Neurofibromatosis 1: closing the GAP between mice and men. Curr Opin Genet Dev 2003, 13: 0-27.
11. Legius E, Marchuk DA, Collins FS, Glover TW: Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993, 3:122-126.
12. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, Glover TW: TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994, 10:250-255.
13. Leroy K, Dumas V, Martin-Garcia N, Falzone MC, Voisin MC, Wechsler J, Revuz J, Creange A, Levy E, Lantieri L, Zeller J, Wolkenstein P: Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol 2001, 137:908-913.
14. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, et al.: Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 1990, 87:5435-5439.
15. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T: Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286:2172-2176.
16. Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM: Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 1999, 155:1855-1860.
17. Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM: Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol 1999, 155:1885-1891.
18. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN: Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 1999, 155:1879-1884.
19. DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W, Vass WC, Viskochil D, Ratner N: Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000, 105:1233-1241.
20. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, Gronchi A, Colecchia M, Pierotti MA, Pilotti S: p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 2003, 9:4132-4138.
21. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM: Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996, 14: 57-460.
22. Paradis V, Bieche I, Dargere D, Laurendeau I, Nectoux J, Degott C, Belghiti J, Vidaud M, Bedossa P: A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology 2003, 124:651-659.
23. Levy P, Bieche I, Leroy K, Parfait B, Wechsler J, Laurendeau I, Wolkenstein P, Vidaud M, Vidaud D: Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Clin Cancer Res 2004, 10:3763-3771.
24. Latil A, Bieche I, Chene L, Laurendeau I, Berthon P, Cussenot O, Vidaud M: Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res 2003, 9:5477-5485.
25. Kindblom LG, Ahlden M, Meis-Kindblom JM, Stenman G: Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch 1995, 427:19-26.
26. Garratt AN, Britsch S, Birchmeier C: Neuregulin, a factor with many functions in the life of a schwann cell. Bioessays 2000, 22:987-996.
27. Feltri ML, Scherer SS, Nemni R, Kamholz J, Vogelbacker H, Scott MO, Canal N, Quaranta V, Wrabetz L: Beta 4 integrin expression in myelinating Schwann cells is polarized, developmentally regulated and axonally dependent. Development 1994, 120:1287-1301.
28. Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, Birchmeier C, Wegner M: The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 2001, 15:66-78.
29. Neumann AA, Reddel RR: Telomere maintenance and cancer - look, no telomerase. Nat Rev Cancer 2002, 2:879-884.
30. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003, 3:46-54.
31. Wurl P, Kappler M, Meye A, Bartel F, Kohler T, Lautenschlager C, Bache M, Schmidt H, Taubert H: Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 2002, 359:943-945.
32. Melino G, De Laurenzi V, Vousden KH: p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002, 2:605-615.
33. Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000, 10:415-433.
34. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252.
35. Chang MS, McNinch J, Basu R, Simonet S: Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem 1994, 269:25277-25282.
36. Fujioka T, Kolson DL, Rostami AM: Chemokines and peripheral nerve demyelination. J Neurovirol 1999, 5: 7-31.
37. O'Donovan N, Galvin M, Morgan JG: Physical mapping of the CXC chemokine locus on human chromosome 4. Cytogenet Cell Genet 1999, 84:39-42.
38. Koga T, Iwasaki H, Ishiguro M, Matsuzaki A, Kikuchi M: Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis. J Pathol 2002, 197:98-107.
39. Hesson L, Dallol A, Minna JD, Maher ER, Latif F: NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 2003, 22:947-954.
40. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25: 15-319.
41. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ: RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003, 278:28045-28051.
42. Zhang S, Chang MC, Zylka D, Turley S, Harrison R, Turley EA: The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem 1998, 273:11342-11348.
43. Maxwell CA, Keats JJ, Crainie M, Sun X, Yen T, Shibuya E, Hendzel M, Chan G, Pilarski LM: RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 2003, 14:2262-2276.
44. Cho RJ, Huang M, Campbell MJ, Dong H, Steinmetz L, Sapinoso L, Hampton G, Elledge SJ, Davis RW, Lockhart DJ: Transcriptional regulation and function during the human cell cycle. Nat Genet 2001, 27:48-54.
45. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG: FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 2002, 62:4773-4780.
46. Sasaki H, Hui C, Nakafuku M, Kondoh H: A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development 1997, 124:1313-1322.
47. Yoon JW, Kita Y, Frank DJ, Majewski RR, Konicek BA, Nobrega MA, Jacob H, Walterhouse D, Iannaccone P: Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 2002, 277:5548-5555.
48. Louro ID, Bailey EC, Li X, South LS, McKie-Bell PR, Yoder BK, Huang CC, Johnson MR, Hill AE, Johnson RL, Ruppert JM: Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. Cancer Res 2002, 62: 867-5873.
49. Ruiz i Altaba A, Sanchez P, Dahmane N: Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002, 2:361-372.
50. Villavicencio EH, Walterhouse DO, Iannaccone PM: The sonic hedgehog-patched-gli pathway in human development and disease. Am J Hum Genet 2000, 67:1047-1054.
51. Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, Zimmer A, Muller U, Samson E, Quintanilla-Martinez L: Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000, 275:28341-28344.
52. Evliyaoglu C, Carroll R, Folkerth R, Bello L, Bruns DE, Black PM: Parathyroid hormone-related protein and its receptor in human glial tumors. Acta Neurochir (Wien) 2000, 142:871-878.
53. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y: Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995, 72:55-63.
54. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG, Perry A: Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 2002, 161:665-672.
55. Joyce JA, Lam WK, Catchpoole DJ, Jenks P, Reik W, Maher ER, Schofield PN: Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. Hum Mol Genet 1997, 6: 543-1548.
56. Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R, Vidaud M: Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 2001, 61:1652-1658.
57. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M: Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999, 45:1148-1156.
58. Mann H, Whitney D: On a test of whether one of two random variables is stochastically larger than the other. Annals of Mathematical Statistics 1947, 18:50-60.
59. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.